Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Asada N, Ando J, Takada S, Yoshida C, Usuki K, Shinagawa A, Ishizawa K, Miyamoto T, Iida H, Dobashi N, Okubo S, Honda H, Soshin T, Nishimura Y, Tsutsui A, Mukai H, Yamamoto K. Asada N, et al. Among authors: usuki k. Jpn J Clin Oncol. 2023 Jun 29;53(7):595-603. doi: 10.1093/jjco/hyad027. Jpn J Clin Oncol. 2023. PMID: 37017320 Free PMC article. Clinical Trial.
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.
Naoe T, Saito A, Hosono N, Kasahara S, Muto H, Hatano K, Ogura M, Masunari T, Tanaka M, Usuki K, Ishikawa Y, Ando K, Kondo Y, Takagi Y, Takada S, Ishikawa M, Choi I, Sano A, Nagai H. Naoe T, et al. Among authors: usuki k. Cancer Immunol Immunother. 2023 Aug;72(8):2865-2871. doi: 10.1007/s00262-023-03432-4. Epub 2023 Apr 24. Cancer Immunol Immunother. 2023. PMID: 37093243 Free PMC article. Clinical Trial.
Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant.
Shimizu H, Najima Y, Kako S, Tanaka M, Fujiwara SI, Mori T, Usuki K, Gotoh M, Hagihara M, Tsukada N, Oniduka M, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Yano S, Ohashi K, Takahashi S, Okamoto S, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Among authors: usuki k. J Infect Chemother. 2023 Dec;29(12):1103-1108. doi: 10.1016/j.jiac.2023.07.015. Epub 2023 Aug 1. J Infect Chemother. 2023. PMID: 37532223
Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.
Nakagawa N, Ishiyama K, Usuki K, Takada S, Tomikawa T, Handa H, Katsuoka Y, Hirano D, Sezaki N, Sumi M, Fujisawa S, Taniguchi Y, Mugitani A, Yoshimura T, Ohtsuka E, Takase K, Suehiro Y, Ota S, Kajiguchi T, Maeda T, Yamamoto M, Ohtake S, Katsumi A, Kiyoi H, Matsumura I, Miyazaki Y. Nakagawa N, et al. Among authors: usuki k. Ann Hematol. 2024 Jan;103(1):307-320. doi: 10.1007/s00277-023-05527-5. Epub 2023 Nov 8. Ann Hematol. 2024. PMID: 37940714
Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y, Ochiai T, Hashimoto Y, Ichii M, Okatani T, Omura H, Nakajima K, Sasaki M, Ando J, Takaku T, Koike M, Izumiyama K, Hiraga J, Yano T, Usuki K, Ohtsuka E, Yokoyama K, Oyake T, Takahashi N, Nishida T, Nakao T, Fukuda Y, Akasaka T, Mugitani A, Ando M, Komatsu N. Edahiro Y, et al. Among authors: usuki k. Hematology. 2024 Dec;29(1):2340149. doi: 10.1080/16078454.2024.2340149. Epub 2024 Apr 16. Hematology. 2024. PMID: 38626148 Free article.
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
Shimizu H, Kato J, Tanoue S, Kimura SI, Tachibana T, Hatano K, Usuki K, Taguchi J, Hagihara M, Tsukada N, Harada K, Takahashi S, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Handa H, Hatta Y, Nakaseko R, Yano S, Ohashi K, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Among authors: usuki k. Leuk Res. 2024 Sep;144:107562. doi: 10.1016/j.leukres.2024.107562. Epub 2024 Aug 20. Leuk Res. 2024. PMID: 39178610
A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes.
Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, Kubonishi S, Morita Y, Nakashima Y, Onodera K, Suzuki K, Suzuki T, Tamai Y, Usuki K, Yokota A, Yonaga H, Hayakawa J, Midorikawa S, Nishio M, Suda M, Matsue K. Kosugi H, et al. Among authors: usuki k. Int J Hematol. 2024 Nov 21. doi: 10.1007/s12185-024-03872-3. Online ahead of print. Int J Hematol. 2024. PMID: 39572468
323 results